This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

HomeUncontrolled UCWhy Patients SettlePrevalence & ImpactDisease NavigatorResources
The prevalence and impact of uncontrolled UC Patients with UC frequently experience ongoing symptoms on conventional therapies or lose response over time.2-4

of patients on conventional therapy reported ongoing symptoms of rectal bleeding*2

of patients on 5-aminosalicylates
(5-ASA) maintenance therapy failed
to maintain clinical or endoscopic remission at 6–12 months†3

of patients with moderate
to severe UC had significant worsening of UC or onset of
acute symptoms after initiating immunomodulating therapy
(mean of ~5 months)‡4

References*The UC-CARES study was an observational, multinational, multicentre, retrospective chart review including cross-sectional collection of patient-reported outcomes from patients with UC (N=150) carried out in 11 European countries.2
†Analysis of 10 studies with a total of 3,910 participants who received once daily 5-ASA.3
‡Retrospective analysis of claims data from the PharMetrics database, which included integrated claims information from 95 managed care health plans spanning all 4 United States Census regions and covering more than 61 million unique patients from 1997 to 2010. 2,136 patients were included.4 Corticosteroid (CS) reliance or excessive use is common and often avoidable in patients with UC.5 References§Steroid dependency or excess was defined as the presence during the preceding 12-month period of ≥1 of: the prescription of >1 steroid course; the inability to wean steroids below 10 mg QD prednisolone or 3 mg QD budesonide within 3 months of initiation; or disease flare within 3 months of stopping steroids. To determine the extent to which doctors had sought to avoid steroid dependency or excess, a standardised list of potential reasons for dependency or excess was agreed and each reason was allocated to 1 of 4 sections: 1) non-inflammatory bowel disease (IBD) prescribing; 2) prescribing where no alternative existed or where appropriate preventative measures were taken; 3) prescribing where relevant alternatives were suboptimally explored; or 4) prescribing where relevant alternatives were not explored. For all cases, meeting the criteria for steroid dependency or excess, relevant clinic letters, biochemical parameters and endoscopy reports were collated and anonymised before being centrally allocated for blinded peer review by a co-author from a different centre, who assigned each case to 1 of 4 pre-agreed categories using a scoring template.5
Data were collected from unselected consecutive IBD patients attending outpatient clinics over 3 months in July–September 2015. Data were obtained for a total of 1,176 patients; 567 (48%) were diagnosed with Crohn's disease (CD), 575 (49%) with UC and 34 (3%) from IBD-unclassified.5A substantial proportion of patients with IBD are not prescribed advanced therapies despite being appropriate for treatment, according to study criteria.6 References**Criteria applied to identify patients with IBD who are potentially appropriate for advanced therapies include patients with steroid-refractory active disease, patients with steroid dependency, patients with intolerance or contraindication to conventional therapies and/or patients with severe disease that has relapsed.6
††Retrospective observational study; data were collected from Italian Healthcare Departments’ administrative databases. The study sample covered approximately 11.3% of the overall Italian population; 26,781 patients diagnosed with IBD were identified, considering all available periods in the database.6Find the resources to help look behind “OK” Resources LoadingReferences:References: 
1.  Rubin OT et al. lnflamm Bowel Dis 2017;23:494-501.
2. Peyrin-Biroulet Let al. Dig Liver Dis 2016;48:601-607.
3. Murray A et al. Cochrane Database Syst Rev 2020;8:C0000544.
4. Loftus EV et al. lnflamm Bowel Dis 2014;20:1361-1367.
5. Selinger CP et al. Aliment Pharmacol Ther 2017;46:964-973.
6. Esposti LO et al. Dig Liver Dis 2023. doi:10.1016/j.dld.2023.04.022.Kicker Why patients settle

Why might patients with UC settle for “OK”?

Learn moreLoadingKicker Resources

Resources to help look behind “OK” for patients’ UC

Learn moreLoadingReferences:References: 
1.  Rubin OT et al. lnflamm Bowel Dis 2017;23:494-501.
2. Peyrin-Biroulet Let al. Dig Liver Dis 2016;48:601-607.
3. Murray A et al. Cochrane Database Syst Rev 2020;8:C0000544.
4. Loftus EV et al. lnflamm Bowel Dis 2014;20:1361-1367.
5. Selinger CP et al. Aliment Pharmacol Ther 2017;46:964-973.
6. Esposti LO et al. Dig Liver Dis 2023. doi:10.1016/j.dld.2023.04.022.

Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information.

PP-UNP-GBR-7064. February 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​